7th IAS Conference on HIV Pathogenesis, Treatment and Prevention*

June 30-July 3, 2013; Kuala Lumpur, Malaysia
CCO is the official provider of online scientific analysis of IAS 2013, through Capsule Summaries, audio podcasts, and CME-certified slides

Clinical Impact of New Data From IAS 2013


Similar rates of spontaneous clearance and SVR to treatment in reinfected patients vs those with initial HCV infection among HIV-infected individuals.

Released: July 5, 2013

Mild to moderate injection-site reactions were observed with both agents but were tolerable and self-limiting.

Released: July 3, 2013

Greater efficacy observed with tenofovir/emtricitabine vs abacavir/lamivudine, and for integrase inhibitors and vs NNRTIs as third drug.

Released: July 5, 2013

Nearly 5-fold increased risk of hip fracture and 75% increased risk of all clinical fractures among HIV-infected patients in large Spanish public healthcare system cohort.

Released: July 3, 2013

In a phase III, 48-week study, the reduced efavirenz dose achieved noninferior rates of HIV-1 RNA < 200 copies/mL and appeared to be associated with a slightly lower frequency of treatment-related adverse events.

Released: July 5, 2013

Despite lack of access to viral load and genotypic resistance tests, use of recycled NRTIs in second-line lopinavir/ritonavir-based ART proved effective for disease control.

Released: July 5, 2013

At primary endpoint, virologic suppression was achieved by 71% of patients treated with dolutegravir vs 64% treated with raltegravir, each with an optimized background regimen, with similar safety and tolerability.

Released: July 5, 2013

NRTI-containing regimen associated with significantly greater loss of proximal femur and lumbar spine BMD loss at Week 48 in patients who had experienced virologic failure on a first-line NNRTI-based regimen.

Released: July 5, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
ViiV Healthcare
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?